trending Market Intelligence /marketintelligence/en/news-insights/trending/lpQrwk1HhKfrN4Wx_W4c4g2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Innovent, Shenogen Pharma to develop combination treatment for advanced cancer

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Innovent, Shenogen Pharma to develop combination treatment for advanced cancer

Hong Kong-listed Innovent Biologics Inc. is partnering with privately held Shenogen Pharma Group Ltd. to develop a combination treatment for advanced cancer.

Under the collaboration, the companies will evaluate Innovent's PD-1 class checkpoint inhibitor Tyvyt in combination with Shenogen Pharma's investigational monoclonal antibody SNG1005 in patients with advanced cancer.

Tyvyt, or sintilimab, is an immuno-oncology therapy jointly developed by Innovent and Indianapolis-based Eli Lilly and Co., and is currently approved to treat classical Hodgkin's lymphoma in China. Innovent CFO Ronnie Ede previously told S&P Global Market Intelligence that the company sold 19,000 units of Tyvyt in the first three weeks following the product's launch in the first quarter of 2019.

SNL Image

Shenogen Pharma has completed multiple mid-stage studies for SNG1005 in the U.S., with a late-stage trial protocol approved by the U.S. Food and Drug Administration.

Shenogen Pharma also owns the full development and commercialization rights to SNG1005 in Greater China. China's National Medical Products Administration has approved its investigational new drug application for SNG1005 in breast cancer which has spread into the brain and a clinical trial is planned.